Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Abstract only LBA4518 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract wi...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 30; no. 15_suppl; p. LBA4518
Main Authors Ryan, Charles J., Smith, Matthew Raymond, De Bono, Johann Sebastian, Molina, Arturo, Logothetis, Christopher, De Souza, Paul L., Fizazi, Karim, Mainwaring, Paul N., Piulats Rodriguez, Jose Maria, Ng, Siobhan, Carles, Joan, Mulders, Peter, Kheoh, Thian San, Griffin, Thomas W., Small, Eric Jay, Scher, Howard I., Rathkopf, Dana E.
Format Journal Article
LanguageEnglish
Published 20.05.2012
Online AccessGet full text

Cover

More Information
Summary:Abstract only LBA4518 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2012.30.15_suppl.lba4518